Amgen Framtida tillväxt
Future kriterier kontrolleras 2/6
Amgen förväntas öka intäkter och intäkter med 7.3% respektive 3% per år. EPS förväntas tillväxt med 7% per år. Avkastningen på eget kapital förväntas bli 101.1% om 3 år.
Viktig information
7.3%
Tillväxttakt i vinsten
7.03%
Tillväxttakt för EPS
| Biotechs vinsttillväxt | 27.4% |
| Intäkternas tillväxttakt | 3.0% |
| Framtida avkastning på eget kapital | 101.10% |
| Bevakning av analytiker | Good |
| Senast uppdaterad | 13 Aug 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Uppdatering av berättelse • Aug 06
AMGN: Fair Outlook Weighs Pipeline Execution Against Cybersecurity And Regulatory Risks
Amgen's updated analyst price target reflects a move higher, supported by recent upward revisions to earnings estimates and increased confidence from analysts in the company's Q2 performance and late stage pipeline catalysts, including MariTide and key cardiovascular programs. Analyst Commentary Recent Street research on Amgen shows a broadly constructive tone, with many firms lifting price targets after Q2 results while still flagging execution and timing risks around key programs such as MariTide and olpasiran.Seeking Alpha • Aug 05
Amgen: First $10 Billion Quarter, More Growth Ahead
Summary Amgen Inc. delivered a strong Q2 results, beating revenue and EPS estimates, and raised full-year guidance by $1 billion and $0.50, respectively. Despite $7 billion in LOE headwinds, Amgen’s commercial portfolio—driven by Repatha, Uplizna, Evenity, Tezspire, and Imdelltra—continues to outperform expectations. Key pipeline catalysts, including MariTide and olpasiran phase 3 readouts, are expected in 2027–2028, with near-term pipeline news flow remaining light. AMGN’s $43.3 billion net debt limits major M&A, but in-licensing and bolt-on deals remain viable; BeOne Medicines stake offers potential balance sheet improvement. Read the full article on Seeking Alpha
Ny berättelse • Jul 19
A transitional big-pharma giant holding a speculative premium driven by obesity hype, masking severe revenue erosion.
The "Amgen 2027 Bull Case" relies on a classic top-line fallacy: assuming that macro obesity market growth and FDA's CNPV (Commissioner’s National Priority Voucher) tailwinds will automatically trigger a re-rating. Here is the cold, data-driven reality: 1.
Uppdatering av berättelse • Jul 10
AMGN: IRS Dispute And Regulatory Setbacks Will Pressure Future Returns
Amgen's updated analyst price target now reflects a fair value estimate of $252.61. Analysts point to refined revenue and margin assumptions, a slightly higher discount rate, and sector-level research that highlights both supportive biotech conditions and company-specific model updates following recent earnings and regulatory disclosures.Uppdatering av berättelse • Jun 14
AMGN: IRS Dispute And Tax Overhang Will Pressure Future Returns
Narrative Update on Amgen Analysts have adjusted Amgen's fair value estimate by about $1 to $244.55 as they balance a lower discount rate and slightly higher projected profit margins against more cautious revenue growth assumptions and recent shifts in Street price targets tied to the ramp of Uplizna and ongoing IRS dispute commentary. Analyst Commentary Recent Street research on Amgen has been mixed, with some firms raising price targets around the launch of Uplizna in generalized myasthenia gravis and others trimming targets as they factor in tax uncertainty and differing views on long term growth drivers.Uppdatering av berättelse • May 31
AMGN: Fair Outlook Balances Rare Disease Potential With Expanded Manufacturing Investment
Amgen's fair value estimate has shifted modestly higher to about $352 per share, up from roughly $350. This reflects analysts' mixed price target revisions around $427 and updated expectations for rare disease and other growth drivers.Uppdatering av berättelse • May 14
AMGN: Fair Outlook Weighs Pipeline Execution Against Expanded Manufacturing Commitments
Analysts have nudged the Amgen price target slightly lower to about $350. This reflects a modest increase in the discount rate, slightly softer revenue growth assumptions and a small reduction in the future P/E multiple, partly offset by a higher projected profit margin and a mix of recent upgrades, downgrades and price target revisions across the Street.Uppdatering av berättelse • Apr 28
AMGN: Recent Rally And Trial Uncertainty Will Pressure Future Returns
Amgen's fair value estimate has moved from about $230.89 to $243.49 as analysts factor in a series of higher price targets from firms across the Street, balanced by several neutral initiations. These initiations point to solid fundamentals but mixed views on potential upside from this level.
Uppdatering av berättelse • Apr 14
AMGN: Diversified Autoimmune And Cardiovascular Pipeline Will Support Future Cash Generation
Analysts have lifted Amgen's average price target, with changes such as the recent $10, $17, $6, $10 and $15 upward revisions reflecting updated views on its pipeline progress, commercial execution, and refreshed financial models. Analyst Commentary Recent Street research on Amgen shows a cluster of higher price targets and fresh coverage that centers on its pipeline, commercial performance, and updated financial models.Uppdatering av berättelse • Mar 30
AMGN: Obesity And Cardiovascular Pipeline Will Support Future Cash Generation
Analysts kept the $432 price target for Amgen steady, reflecting a balance between recent target increases tied to pipeline and commercial updates, and newer Hold and Equal Weight initiations that describe the shares as fairly valued after a strong run. Analyst Commentary Recent research on Amgen shows a mix of optimism and caution around valuation, with bullish analysts highlighting commercial execution and the expanding pipeline, while newer initiations frame the shares as fairly valued after a strong move higher.Uppdatering av berättelse • Mar 16
AMGN: Fair Outlook Balances Patent Expiries With Late Stage Pipeline Potential
The Analyst Price Target for Amgen has been updated from $327.74 to $350.03 as analysts factor in recent price target increases tied to stronger near term commercial execution, added value from key Phase 3 pipeline assets, and a shift toward discounted cash flow based models that emphasize improved margin assumptions and a slightly lower discount rate. Analyst Commentary Recent Street commentary around Amgen reflects a mix of optimism about the current execution and pipeline, alongside ongoing debate about valuation, product risks, and long term earnings durability.Uppdatering av berättelse • Mar 02
AMGN: Obesity And Cardiovascular Pipeline Will Drive Future Cash Generation
The analyst price target for Amgen in this narrative has moved to $432. Analysts point to updated DCF assumptions, slightly lower revenue growth and profit margin inputs, and a modestly higher future P/E multiple supported by recent price target increases across the Street and ongoing confidence in the pipeline and guidance.Uppdatering av berättelse • Feb 16
AMGN: Long Patent Expiries And Heavier Spending Will Pressure Future Earnings
Analysts have lifted their price targets on Amgen by about $12 to reflect updated views on fair value, profitability, and future P/E assumptions, while also factoring in a higher discount rate and lower projected revenue growth. Analyst Commentary Recent research on Amgen points to a split view, with several firms lifting price targets while others are turning more cautious.Analysartikel • Feb 11
Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52
Amgen Inc.'s ( NASDAQ:AMGN ) dividend will be increasing from last year's payment of the same period to $2.52 on 6th of...Uppdatering av berättelse • Feb 02
AMGN: Obesity And Cardiovascular Pipeline Will Shape Long-Term Cash Generation
Analysts have nudged their Amgen price targets higher by about $10 to $20, citing a shift toward discounted cash flow analysis, steady execution in legacy products, and increased confidence in the obesity and cardiovascular pipeline. Analyst Commentary Recent research on Amgen highlights a wide range of opinions, but there is a clear cluster of bullish analysts who are leaning into higher price targets and more constructive ratings.Analysartikel • Jan 21
Amgen's (NASDAQ:AMGN) Shareholders Will Receive A Bigger Dividend Than Last Year
Amgen Inc. ( NASDAQ:AMGN ) has announced that it will be increasing its dividend from last year's comparable payment on...Uppdatering av berättelse • Jan 19
AMGN: Obesity And Cardiovascular Pipeline Will Support Long-Term Upside Potential
Analysts have raised their price targets on Amgen into a higher range, with moves such as BofA's shift to a discounted cash flow approach and UBS's upgraded view on earnings and pipeline potential, even as others highlight upcoming patent expiries and spending needs that temper expectations. Analyst Commentary Recent research on Amgen shows a mix of cautious and constructive views, but the price target moves cluster in a higher range, with several firms now anchoring their models around pipeline contributions and cash flow potential alongside the existing portfolio.Analysartikel • Jan 07
Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52
Amgen Inc. ( NASDAQ:AMGN ) will increase its dividend from last year's comparable payment on the 6th of March to $2.52...Uppdatering av berättelse • Jan 05
AMGN: Patent Expiries And New Drug Launches Will Shape Future Performance
Analysts nudged their fair value estimate for Amgen higher to about $328 per share, up from roughly $323. This reflects slightly firmer revenue expectations and a higher assumed future P/E, balanced against more conservative profit margin assumptions and mixed Street views that highlight both the stability of the core business and uncertainty around patent expiries and new launches.Uppdatering av berättelse • Dec 15
AMGN: Margin Expansion And Pipeline Progress Will Drive Long-Term Upside Potential
Analysts have nudged their fair value estimate for Amgen higher to approximately $425 from about $405, reflecting a more constructive view on the company as a defensive large cap biotech with improving margin potential and an innovation pipeline that, while still facing patent expiry and execution risks, is increasingly seen as capable of supporting long term earnings power. Analyst Commentary Recent Street research on Amgen highlights a balanced but gradually improving sentiment backdrop, with a growing cohort of bullish analysts positioning the company as a core large cap biotech holding.Uppdatering av berättelse • Nov 30
AMGN: Future Pipeline Progress And Revenue Diversification Will Shape Performance
Amgen's analyst price target has been raised modestly to $322.88, with analysts citing stable revenue, recent guidance increases, and optimism around its pipeline despite ongoing challenges related to patent expiries. Analyst Commentary Recent Street research provides a nuanced view of Amgen’s valuation, outlook, and potential risk factors, with opinions split between those optimistic about its growth trajectory and those concerned about near-term challenges.Uppdatering av berättelse • Nov 16
AMGN: Future Pipeline Progress And Profit Margins Will Guide Near-Term Performance
Amgen's fair value target has increased by approximately $7 to $318.51, as analysts highlight robust profit margin improvement and sustained pipeline progress in their latest updates. Analyst Commentary Recent updates from Wall Street reveal a mix of optimism and caution surrounding Amgen’s outlook.Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2028 | 41,242 | 9,890 | 15,104 | 15,993 | 27 |
| 12/31/2027 | 40,003 | 9,394 | 14,476 | 14,818 | 31 |
| 12/31/2026 | 38,890 | 8,598 | 11,608 | 14,109 | 28 |
| 6/30/2026 | 38,095 | 8,743 | 10,175 | 12,478 | N/A |
| 3/31/2026 | 37,220 | 7,800 | 8,597 | 10,756 | N/A |
| 12/31/2025 | 36,751 | 7,711 | 8,100 | 9,958 | N/A |
| 9/30/2025 | 35,971 | 7,005 | 11,539 | 13,126 | N/A |
| 6/30/2025 | 34,917 | 6,619 | 10,605 | 12,013 | N/A |
| 3/31/2025 | 34,126 | 5,933 | 10,915 | 12,192 | N/A |
| 12/31/2024 | 33,424 | 4,090 | 10,394 | 11,490 | N/A |
| 9/30/2024 | 32,534 | 4,230 | 6,283 | 7,257 | N/A |
| 6/30/2024 | 30,934 | 3,130 | 5,481 | 6,446 | N/A |
| 3/31/2024 | 29,532 | 3,763 | 7,098 | 8,096 | N/A |
| 12/31/2023 | 28,190 | 6,717 | 7,359 | 8,471 | N/A |
| 9/30/2023 | 26,833 | 7,566 | 9,379 | 10,582 | N/A |
| 6/30/2023 | 26,582 | 7,979 | 9,685 | 10,800 | N/A |
| 3/31/2023 | 26,190 | 7,917 | 7,531 | 8,621 | N/A |
| 12/31/2022 | 26,323 | 6,552 | 8,785 | 9,721 | N/A |
| 9/30/2022 | 26,330 | 6,835 | 8,997 | 9,880 | N/A |
| 6/30/2022 | 26,384 | 6,576 | 8,355 | 9,320 | N/A |
| 3/31/2022 | 26,316 | 5,723 | 8,417 | 9,321 | N/A |
| 12/31/2021 | 25,979 | 5,893 | 8,381 | 9,261 | N/A |
| 9/30/2021 | 25,767 | 5,609 | 7,840 | 8,606 | N/A |
| 6/30/2021 | 25,484 | 5,746 | 8,897 | 9,556 | N/A |
| 3/31/2021 | 25,164 | 7,085 | 9,835 | 10,467 | N/A |
| 12/31/2020 | 25,424 | 7,264 | 9,889 | 10,497 | N/A |
| 9/30/2020 | 24,987 | 7,352 | 10,235 | 10,858 | N/A |
| 6/30/2020 | 24,301 | 7,299 | 10,209 | 10,867 | N/A |
| 3/31/2020 | 23,966 | 7,675 | N/A | 9,439 | N/A |
| 12/31/2019 | 23,362 | 7,842 | N/A | 9,150 | N/A |
| 9/30/2019 | 23,395 | 8,067 | N/A | 9,830 | N/A |
| 6/30/2019 | 23,562 | 7,958 | N/A | 9,726 | N/A |
| 3/31/2019 | 23,750 | 8,075 | N/A | 10,414 | N/A |
| 12/31/2018 | 23,747 | 8,394 | N/A | 11,296 | N/A |
| 9/30/2018 | 23,319 | 2,202 | N/A | 11,114 | N/A |
| 6/30/2018 | 23,188 | 2,364 | N/A | 11,295 | N/A |
| 3/31/2018 | 22,939 | 2,219 | N/A | 11,519 | N/A |
| 12/31/2017 | 22,849 | 1,979 | N/A | 11,177 | N/A |
| 9/30/2017 | 23,012 | 8,178 | N/A | 11,265 | N/A |
| 6/30/2017 | 23,050 | 8,174 | N/A | 10,473 | N/A |
| 3/31/2017 | 22,928 | 7,893 | N/A | 10,824 | N/A |
| 12/31/2016 | 22,991 | 7,722 | N/A | 10,354 | N/A |
| 9/30/2016 | 22,562 | 7,587 | N/A | 9,327 | N/A |
| 6/30/2016 | 22,474 | 7,433 | N/A | 9,557 | N/A |
| 3/31/2016 | 22,156 | 7,216 | N/A | 10,164 | N/A |
| 12/31/2015 | 21,662 | 6,939 | N/A | 9,731 | N/A |
| 9/30/2015 | 21,457 | 6,433 | N/A | 10,103 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: AMGN s prognostiserade vinsttillväxt ( 7.3% per år) är över sparkvoten ( 3.7% ).
Resultat vs marknad: AMGN s intäkter ( 7.3% per år) förväntas växa långsammare än marknaden för US ( 17.2% per år).
Höga tillväxtresultat: AMGN s intäkter förväntas växa, men inte avsevärt.
Intäkt vs marknad: AMGN s intäkter ( 3% per år) förväntas växa långsammare än marknaden för US ( 13% per år).
Hög tillväxtintäkter: AMGN s intäkter ( 3% per år) förväntas växa långsammare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: AMGN s avkastning på eget kapital förväntas bli mycket hög om 3 år ( 101.1 %).
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/13 14:39 |
| Aktiekurs vid dagens slut | 2026/08/13 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Amgen Inc. bevakas av 61 analytiker. 31 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| Emily Field | Barclays |